Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cerus Corp (CERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 895,554
  • Shares Outstanding, K 135,689
  • Annual Sales, $ 51,330 K
  • Annual Income, $ -60,590 K
  • 36-Month Beta 1.41
  • Price/Sales 11.20
  • Price/Cash Flow N/A
  • Price/Book 9.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.41 +22.00%
on 01/24/19
6.71 -1.64%
on 02/21/19
+0.92 (+16.20%)
since 01/18/19
3-Month
4.70 +40.28%
on 12/20/18
6.71 -1.64%
on 02/21/19
+1.27 (+23.83%)
since 11/21/18
52-Week
4.15 +59.04%
on 02/23/18
8.05 -18.01%
on 08/03/18
+2.42 (+57.89%)
since 02/21/18

Most Recent Stories

More News
Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Varonis Systems, Inc. (NASDAQ:VRNS),...

RPAI : 12.61 (unch)
ALDR : 14.17 (+0.93%)
MPAA : 20.62 (-2.60%)
VRNS : 54.55 (+1.85%)
DLB : 64.80 (-0.61%)
CERS : 6.60 (-0.90%)
Cerus to Release Fourth Quarter and Full Year 2018 Results on February 26, 2019

Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market. The...

CERS : 6.60 (-0.90%)
Cerus Announces Preliminary Fourth Quarter and Full Year 2018 Product Revenue

Cerus Corporation (Nasdaq:CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2018 and provided 2019 product revenue guidance.

CERS : 6.60 (-0.90%)
William Moore Appointed as Cerus Corporation's Senior Vice President of Manufacturing Operations and Supply Chain

Cerus Corporation (Nasdaq:CERS) announced today the appointment of William Moore to the newly created position of Senior Vice President of Manufacturing Operations and Supply Chain for Cerus,...

DGX : 87.81 (-1.27%)
CERS : 6.60 (-0.90%)
Cerus Announces First Patient Enrolled in the Phase 3 ReCePI Study

Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study...

CERS : 6.60 (-0.90%)
Emerging Medical Device Market Expected to Exceed $400 Billion by 2023

Financialnewsmedia.com News Commentary

ETST : 0.6730 (-3.86%)
PBYI : 26.13 (-2.32%)
JNJ : 135.42 (-0.68%)
CERS : 6.60 (-0.90%)
TRXC : 3.13 (+3.64%)
Cerus Completes CE Mark Submission for INTERCEPT Red Blood Cells

Cerus Corporation (Nasdaq:CERS) today announced that it has filed for CE Mark registration for the Company's INTERCEPT red blood cell (RBC) system.

CERS : 6.60 (-0.90%)
Best Relative Performance in the Health Care Supplies Industry Detected in Shares of Cerus Corp (CERS , NEOG , XRAY , WST , QDEL )

We looked at the Health Care Supplies industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We...

XRAY : 41.76 (-2.18%)
NEOG : 61.43 (-2.07%)
CERS : 6.60 (-0.90%)
Best Relative Performance in the Health Care Supplies Industry Detected in Shares of Cooper Cos Inc (COO , ALGN , CERS , STAA , HAE )

We looked at the Health Care Supplies industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We...

COO : 286.33 (+0.60%)
ALGN : 250.23 (-1.40%)
CERS : 6.60 (-0.90%)
American Red Cross Receives Biologics License Application Approval For INTERCEPT Platelets

Cerus Corporation (Nasdaq:CERS) announced today that the American Red Cross has received approval by the U.S. Food and Drug Administration (FDA) for their first biologics license application...

CERS : 6.60 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade CERS with:

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Key Turning Points

2nd Resistance Point 6.80
1st Resistance Point 6.70
Last Price 6.60
1st Support Level 6.51
2nd Support Level 6.41

See More

52-Week High 8.05
Last Price 6.60
Fibonacci 61.8% 6.56
Fibonacci 50% 6.10
Fibonacci 38.2% 5.64
52-Week Low 4.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar